Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
The comparison of treatment effect and co-morbidity between the genders in the Valsartan Heart Failure Trial showed equal benefit of treatment in men and women. Co-morbidities, such as diabetes and coronary artery disease, increased nonfatal cardiac morbidity more in women than in men.
Majahalme
Silja K
SK
Tampere University, Tampere, Finland; Appleton Heart Institute, Appleton, Wisconsin, USA. silja.majahalme@thedacare.org
Baruch
Lawrence
L
Aknay
Nora
N
Goedel-Meinen
Liselotte
L
Hofmann
Monika
M
Hester
Allen
A
Prescott
Margaret Forney
MF
Feliciano
Nancy
N
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000401:mortality; D003920:Diabetes Mellitus / Q000453:epidemiology; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D012720:Severity of Illness Index; D017678:Sex Distribution; D013777:Tetrazoles / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine